Charles River Laboratories InternationalCRL
Recorded

Charles River Laboratories International Jefferies Global Healthcare Conference

Review the key takeaways and the transcript of this earnings call.

Period 0Duration26 minParticipants2

Transcript

Preview the first fifteen paragraphs, organized by speaker.

David WindleyHealthcare Equity Research

I'm Dave Windley with Jefferies Healthcare Equity Research. Appreciate your interest in Jefferies London Healthcare Conference. Our next presenting company is Charles River Labs and the company's CEO, Birgit Girshick, who's taken over just this year. So welcome. We've had you at, I think, at least New York. I can't remember if here, but Yes we certainly have had you in conference settings before, and so appreciate you being here.

David WindleyHealthcare Equity Research

As I said, Birgit has just recently taken over the CEO seat and has rolled out an impressive strategy. I wanted to give you the opportunity to just talk about the changes that you're instituting under your leadership.

Birgit GirshickCEO

Certainly. So thanks, David, for having us. It's always a pleasure to be here. It's actually my second time here in London, and it's a great conference for us to be here. Yes, I've taken over as CEO roughly six months ago, but I've been with Charles River nearly four decades. So what I bring to the CEO role is a lot of knowledge about Charles River, what differentiates us, what our strengths are, but also what our weaknesses are. Based on that, I was basically able to hit the ground running as soon as I was appointed to the role. What I did was roll out a strategic framework called Pathway to Purpose.

Birgit GirshickCEO

We did this to give clarity to our employees and align them around what needs to be done, but also to provide clarity to our board, to our clients, and clarity to our investors, current and potential investors. What Pathway to Purpose is about is the three areas that we need to focus on to continue to be competitive today, but also to be competitive in the future, three years from now, five years from now, or decades from now. What Pathway to Purpose really covers is modernization of our company, and that's something that I have a real urgency about and leaning into a lot. So modernization of our company means that we want to have more scalable, more automated, more digital processes so we can actually be faster and more agile for our clients.

Birgit GirshickCEO

This initiative, called Create the Future, is going to translate and support into $300 million of cost savings between now and the next three years. That is in addition to $300 million of cost savings that we have taken out of the company in the last three years under my leadership. This will translate into approximately 75 basis points of margin improvement in the next few years. We have already made great progress on it. This is an initiative that it's not going to be something that we're going to do, but actually executing on. Just recently, we announced that we implemented an automated production line in our Microbial Solutions facility, increasing capacity by 14%. We talked about Apollo Orchestrate.

Birgit GirshickCEO

Apollo is our client-facing platform that will allow us to digitize our laboratory processes from sample submission through the laboratory all the way into reporting for our Biologics Testing business. The digitization efforts will cover everything from how we structure, organize our data, but also the use of AI. Another important area is our portfolio, and we have made great progress on that. What we want to do is refine our portfolio to make sure that we operate and provide our clients with the highest value services that they really rely on us and really want to buy from us. Earlier this year, we have made two divestitures. Our early discovery assets in Europe was one of them, and our CDMO business that we divested together with our cell supply business. These were two businesses that were great businesses.

Birgit GirshickCEO

However, we are not necessarily the best parent at this stage in the process. In addition, we have made two acquisitions which really strengthen our company. One was a non-human primate facility that allows us to integrate into our supply chain and give our clients the confidence that they actually can run their critical safety assessment studies when they need them. The non-human primate is non-arguably the most critical research model, and this backward integration is incredibly important for us and the industry. We also, at the same time, invested in a NAMs technology. We acquired a company called PathoQuest. This technology will replace in vivo testing in our Biologics Testing business. In addition, it allows us to offer now cell bank characterization, which many of the manufacturers are required to have, from a 20-week normal process down 40%. A real improvement in timelines.

Birgit GirshickCEO

Last but not least, we're focused on client centricity, which the first and the second pillar, modernization and portfolio refinement, actually help us a lot with that. It's also the way we go to market, the way we deal with our clients, the ease of working that our clients experience with a CRO with us. We believe that we are making great progress there. We just signed a strategic partnership, being the primary strategic partner of a top 10 pharmaceutical company. We have worked with this company for a long time and have proven that we are the best partner, and now we were selected the primary partner, which is now literally every biopharmaceutical company selecting Charles River as their top partner. I'm leaning into those areas, and I'm believing that this will provide us with a lot of long-term shareholder value.

David WindleyHealthcare Equity Research

Birgit, on that last point that you made, the completing the sweep, essentially, is 10 of the top 10, or did you even say yesterday 20 of the top 20?

Birgit GirshickCEO

Well, don't want to give exact numbers, but the top biopharmaceutical companies see us as their utmost critical partner.

David WindleyHealthcare Equity Research

Got it. Okay. DSA is your largest business, that's now reached the mid-single-digit organic growth level. You've had four consecutive quarters of book-to-bill above one. Talked about proposals are still kind of accelerating. I just want to kind of test what you're seeing in the market. Is there any client fragility that still remains? How durable does this recovery feel to you and to your sales team?

Birgit GirshickCEO

Yeah, great question, and really important. Something that we are always concerned about and keep certainly looking at our metrics as well as the macroeconomics. So at this stage, we have a very broad-based stabilization and improvement of all metrics that we are looking at. So, revenue growth came from both biotech as well as global biopharma. Net book-to-bill increase came from both client segments. Proposal rates are up, high single, high double digits year-over-year for five consecutive months now. So everything we're looking at shows us that the demand is back, that our clients are back to work, and that the biotech funding is translating into demand, and global biopharma has, for the most part, completed their restructuring and reprioritization. To your question, what is still outstanding? Where do we still would like to see some improvements? There's actually two areas. One of the areas is the very early stage funding or early stage company formation.

Birgit GirshickCEO

That is generally something that we talk about in relation to our CRADL business, but even with DSA demand, in order to have very long-term sustainable demand, we definitely want to see that bounce back a little bit more. The other area that we still not quite happy with is the availability of pricing. This last quarter in our earnings release, we actually talked about that we have walked back discounting a little bit, or in other words, we are implementing slight pricing increases in our proposals. We were able to win some of that work. Our capture rates have stayed up. I have confidence that we're gaining back some of that pricing power.

Birgit GirshickCEO

Even as we do, and assuming this will hold, we have a bit of a longer way to go with that, because as pricing returns in the bookings, we have to anniversary out our backlog first, because that was booked at the lower rates. Sure pricing will come, but it will be a few quarters before we see it in the revenue.

David WindleyHealthcare Equity Research

I appreciate both of those. Just to hover on the pricing for a second, you made the point to me in conversation recently that this point that you just made about some of the older backlog priced less well as what you're seeing now. Can you give us a little bit of chronology there? Where was perhaps pricing bottoming out before it started to improve? Where would that have occurred?

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day